Clinical trial / 2013
Short-term soy isoflavone supplementation did not alter serum hormones or PSA in prostate cancer.
Eighty-six men awaiting prostatectomy were randomized to consume 80 mg daily of isoflavones or a placebo for up to six weeks. Microarray analysis revealed down-regulation of 12 cell cycle control genes and 9 apoptosis genes in tumor tissue from the supplement arm. However, shifts in circulating estrogens, androgens, PSA, and total cholesterol showed no statistically significant differences between groups.
- Study type
- Randomized controlled trial
- Who was studied
- 86 men with localized prostate cancer
- What was measured
- Serum hormones, PSA, cholesterol, and tissue gene expression
THE PAPER
Short-term soy isoflavone intervention in patients with localized prostate cancer: a randomized, double-blind, placebo-controlled trial.
Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, Thrasher JB, Kambhampati S, Keighley J, Van Veldhuizen P. PLoS One, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.